Navigation Links
Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
Date:8/30/2007

WASHINGTON, Aug. 30 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held biotechnology company, today announced that it has hired Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer.

Dr. Stogniew will be responsible for Prestwick's pre-clinical development, regulatory and patent activities around its portfolio of products including its lead product candidate, tetrabenazine, a highly selective and reversible dopamine depletor in Phase 3 clinical trials for potential use as a treatment for chorea associated with Huntington's Disease.

He joins Prestwick most recently from Zelos Therapeutics, where he was Executive Vice President of Development responsible for pre-clinical, regulatory and patent development.

"With 25 years focused on developing drugs and 25 patents to his name, Marty will immediately help Prestwick as we work to execute and enhance our pipeline," said George F. Horner III, President and Chief Executive Officer of Prestwick. "He has made a significant impact in the development of successful drugs such as Anidulafugin, Amifostine and Idarubicin -- all of which are now on the market and positively impacting patients' lives."

Dr. Stogniew worked with Mr. Horner at Vicuron Pharmaceuticals, Inc. as Executive Vice President of Scientific Affairs from 2001 to 2005 before Vicuron was purchased by Pfizer in 2005 for $1.9 billion. Prior to Vicuron, Dr. Stogniew served as Chief Scientific Officer at Next Pharmaceuticals, Inc. and as Vice President of Pharmaceutical Sciences at MedImmune. Dr. Stogniew holds a Ph.D. in Medicinal Chemistry and a B.S. in Pharmacy from the University of Maryland.

About Prestwick

Prestwick is currently managing a portfolio of pipeline product candidates being studied for CNS conditions with significant unmet needs, including Huntington's disease, Parkinson's disease, restless legs syndrome, schizophrenia, autism, Alzheimer's disease and sleep apnea.

Please go to http://www.prestwickpharma.com for more information.


'/>"/>
SOURCE Prestwick Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Traveling stem cell show continues state tour
2. AT&T - BellSouth merger: Revestiture continues
3. Madison biotech continues its climb
4. Brady continues growth through Asian acquisition
5. Transition continues to impact Third Wave financials
6. Line between big pharma, big biotech continues to blur
7. Wisconsin giant continues to dominate the health care IT market
8. API Software continues expansion
9. Third Wave continues molecular diagnostic focus with new CEO
10. Midwest Public-Sector Biotech Continues to Sizzle
11. Corona Optical Systems continues to excite investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 02, 2016 , ... ... -operated small businesses in federally funded research and development is welcome news for ... optics and photonics . , As part of the National Defense Authorization Act ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation of ... lumbar disc production, company President, Jake Lubinski will be traveling to Switzerland from ... disc in Bern, Lucerne, and Zurich to discuss the benefits of a viscoelastic ...
(Date:12/2/2016)... , Dec. 2, 2016 CytRx Corporation ... development company specializing in oncology, today announced the appointment ... sarcoma surgeon, industry consultant, and private healthcare investor, to ... a healthcare leader with clinical and strategic experience at ... CytRx,s Chairman and CEO. "As one of the world,s ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ... pneumatic tube systems for North American hospitals, will present its chain-of-custody solution for ... and Exhibition in Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a ...
Breaking Biology Technology:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
Breaking Biology News(10 mins):